Objectives: There is a paucity of data exploring treatment options for refractory pancreatic cancer. Oxaliplatin has interesting activity in second-line therapy. Fixed-dose-rate gemcitabine (GFDR, 10 mg/m2/min) has shown promising results in patients with advanced pancreatic cancer over standard-dose-rate (30 min) gemcitabine (GSDR). Methods: We conducted a retrospective analysis of the experience of our cancer center with GFDR and oxaliplatin (GEMOX) in patients who failed GSDR. GEMOX consisted of gemcitabine 1,000 mg/m2 over 100 min on day 1 and oxaliplatin 100 mg/m2 over 2 h on day 2 every 2 weeks. Eligible patients were required to have measurable metastatic adenocarcinoma of the pancreas and to have failed prior GSDR. Results: Seventeen patients (median age 62 years) who were treated at the Ohio State University with GEMOX following GSDR failure between November 2003 and January 2008 were included in this study. Twenty-four percent of all patients had a partial response, 29% had stable disease and 47% had progressive disease. The median progression-free survival was 2.6 months and the median overall survival was 6.4 months. There were no unexpected toxicities. Conclusion: GEMOX shows interesting activity and acceptable tolerability in patients with metastatic pancreatic cancer who failed prior GSDR. Our results are consistent with previously published results.

1.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.
2.
Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402–3408.
3.
Rose PG: Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005;15(suppl 1):18–22.
4.
Moschidis A, Papgeorgiou A, Atmatzidis K, Tsalis K, Moschidis E, Livanis J, Chrysogelou E, Mourelatos D, Tsavdaridis D, Harlaftis N: Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice. Chemotherapy 2007;53:153–159.
5.
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509–3516.
6.
Heinemann V, Hinke A, Bock S, Labianca R, Louvet C: Gemcitabine based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. 2007 ASCO Annu Meet Proc, part 1, vol 25, No 18S (June 20 supplement). J Clin Oncol 2007:4515.
7.
Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S, Benson A: Phase III trial of gemcitabine (30 minute infusion) versus gemcitabine [fixed-dose-rate infusion (FDR)] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). 2006 ASCO Annu Meet Proc, part 1, vol 24, No 18S (June 20 supplement). J Clin Oncol 2006:LBA4004.
8.
Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512–1518.
9.
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481–485.
10.
Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopteridis P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005;23:369–375.
11.
Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003;14:580–585.
12.
Baize N, Abu Shalaa A, Berthier F, Demarquay JF, Bernard JL, Rahili A, Piche T, Huet PM, Tran A, Caroli-Bosc FX: Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. Gastroenterol Clin Biol 2005;29:1006–1009.
13.
Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117–123.
14.
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA: Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose-rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195–199.
15.
Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006;24:379–385.
16.
Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013–1016.
17.
Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Riess H, Oettle H: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study (abstract 4508). J Clin Oncol 2008;26(suppl):215.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.